Introduction
============

During aging, a decline in muscle mass coupled with an increase in fat mass has important consequences for older adults.[@b1-ijgm-11-443] Four body composition phenotype characteristics exist in older adults: normal, sarcopenic, obese, and a combination of sarcopenic and obese.[@b2-ijgm-11-443] Although the definition of sarcopenic obesity (SO) combines those of sarcopenia and obesity, few diagnostic methods have been proposed in recent years.[@b2-ijgm-11-443]--[@b4-ijgm-11-443]

Obesity can be diagnosed by total fat mass, percentage body fat, body mass index (BMI), visceral fat area, and waist circumference, while sarcopenia can be diagnosed by appendicular lean mass adjusted for height squared (aLM/height[@b2-ijgm-11-443] or BMI \[aLM/BMI\]).[@b6-ijgm-11-443] The aLM/height[@b2-ijgm-11-443] method has been widely used in many studies, while the aLM/BMI method represents a new clinically relevant criteria for weakness and low muscle mass based on a large, diverse, and well characterized set of populations of community-dwelling elderly persons that permit generalizability of findings.[@b1-ijgm-11-443],[@b5-ijgm-11-443]--[@b9-ijgm-11-443]

The combination of sarcopenia and obesity has a detrimental impact on physical functional status in obese elderly women, which in turn exacerbates disability.[@b2-ijgm-11-443],[@b10-ijgm-11-443] SO is also associated with systemic inflammation (eg, higher C-reactive protein, fibrinogen, interleukin-6 \[IL-6\]), lower handgrip strength, lower lean body mass, higher mortality risk, lower muscle quality caused by fat infiltration, impaired quality of life, higher cardiovascular disease risk, and more physical disabilities when compared with subjects without SO.[@b3-ijgm-11-443],[@b8-ijgm-11-443],[@b11-ijgm-11-443]--[@b16-ijgm-11-443]

Considering that SO research is in its infancy and different mathematical thresholds can over- and under-diagnose this clinical condition, our goal was to 1) apply the newly standardized definition for SO used in previous studies and proposed by the Foundation for the National Institutes of Health (FNIH) and illustrate the prevalence of SO in obese elderly women; 2) observe the degree of impairment of muscle strength, lean body mass, and markers of inflammation in those fulfilling such criteria; and 3) elucidate the association between aLM/BMI with obesity indices and strength parameters.[@b6-ijgm-11-443],[@b8-ijgm-11-443],[@b9-ijgm-11-443],[@b11-ijgm-11-443],[@b17-ijgm-11-443]

We hypothesized that obese elderly women with SO will have higher pro-inflammatory markers when compared to NSO elderly women. Furthermore, we hypothesized that a higher aLM/BMI will be positively associated with lean body mass and muscle strength and negatively associated with obesity indices.

Materials and methods
=====================

Ninety elderly women from a local community were recruited through posters and lectures about the study at the Federal District, Brazil. To be eligible, women needed to be aged ≥60 years with a body fat percentage ≥38% as assessed by dual-energy X-ray absorptiometry (DXA).[@b11-ijgm-11-443],[@b17-ijgm-11-443] Exclusion criteria included history of heart failure, valvular or congenital disease, pacemaker implantation, or osteoarticular disorders. A total of 90 older women were assessed for eligibility and completed a self-report questionnaire that accounted for cardiovascular disease, hypertension, diabetes, osteoporosis, or musculoskeletal conditions that may have precluded participants from safely completing physical function tests assessed in this study. Elderly women were classified as hypertensive and with type 2 diabetes mellitus by the diagnostic criteria used in previous studies.[@b18-ijgm-11-443]--[@b20-ijgm-11-443] From the initial applicants, 26 were excluded (did not meet inclusion criteria) and thus a total of 64 women who met the inclusion criteria were selected to participate. The present study was approved by the Institutional Research Ethic Committee of Catholic University of Brasília (UCB) (protocol \#035/2011). The study design and employed procedures were in accordance with ethical standards and the Declaration of Helsinki. Each participant was fully informed about the risks associated with study participation and gave their written informed consent.

Muscle strength evaluation
--------------------------

Muscle strength was evaluated by the ten-repetition maximum (10 RM) test according to the protocol used in previous research from our laboratory.[@b21-ijgm-11-443],[@b22-ijgm-11-443] The test-retest reproducibility for the leg extension 10 RM was *R*=0.99. In addition, the relative muscle strength was calculated by dividing the 10 RM test value by body mass.[@b23-ijgm-11-443] In addition, the leg extension exercise was chosen because lower limb strength has a strong correlation with elderly survival time and dependency.[@b24-ijgm-11-443]

Blood samples and biochemical parameters
----------------------------------------

Lipid profile glycerol phosphate dehydrogenase/p-chlorophenol in presence of peroxidase, urea (Ureasi-glutamate dehydrogenase), and uric acid (uricase/peroxidase method) were measured by the enzymatic colorimetric method using Autohumalyzer equipment (Human GMBH, Wiesbaden, Germany). High-density lipoprotein cholesterol was determined by ionic exchange followed by colorimetric reaction with the Linco Research Inc. kit (St Louis, MO, USA), and blood glucose was measured by the hexokinase enzymatic assay. IL-6 concentration was measured by Quantikine high-sensitivity commercial enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis, MN, USA). The intraassay coefficient of variation of the kit was 1.5%--5.6% for IL-6. The inter-assay coefficient of variation was 4.3%--6.4% for IL-6. Creatine kinase (CK) concentration was determined by using a commercially available Reflotron CK assay using the Reflotron system (Boehringer Mannheim GmbH, Mannheim, Germany). The measures for CK and IL-6 were performed in triplicate and then averaged.

Body composition
----------------

Body composition procedures have been described in detail elsewhere, and percent body fat and appendicular skeletal muscle mass were determined via DXA (General Electric-GE model 8548 BX1L, year 2005, Lunar DPX type, Software Encore 2005; Rommelsdorf, Germany). The coefficient of variation for the percent body fat estimated by DXA was 10.12% and 12.13% for the SO and nonsarcopenic obesity (NSO) groups, respectively. All metal objects were removed from the participants before the scan.[@b25-ijgm-11-443]

Sarcopenia and SO
-----------------

Prevalence of sarcopenia was defined by the aLM adjusted for BMI \<0.512.[@b6-ijgm-11-443],[@b8-ijgm-11-443] Obesity was considered as a body fat percentage ≥38%. SO was determined if elderly women fulfilled the criteria for both sarcopenia and obesity using these definitions.[@b4-ijgm-11-443]--[@b6-ijgm-11-443],[@b11-ijgm-11-443],[@b17-ijgm-11-443]

Statistical analysis
--------------------

All analyses were conducted with SPSS software version 18.0 (SPSS Inc., Chicago, IL, USA) and the normality was verified by the Shapiro--Wilk test. For the parametric and non-parametric data, an independent Student's *t*-test and Mann--Whitney *U* test were employed, respectively. In addition, the Spearman's rank correlation coefficient was used to test the association of aLM/BMI with biochemical parameters, muscle strength, and body composition. A chi-squared test for proportions (Fisher's exact test when cells with expected values were \<5 for essential hypertension and type 2diabetes mellitus) was also employed. An alpha level of *P*≤0.05 was considered significant. In addition, GraphPad Prism 7.0 software was also used (GraphPad Software, Inc., La Jolla, CA, USA). An effect size *d* of 2.31, a power \>80%, alpha error probability of 0.05, allocation ratio of 1.06, and two tails were considered. The post hoc power analysis was used to calculate the sample size necessary to identify differences between two independent groups. Sixty-two elderly (31 vs 31) women were necessary to identify a difference on aLM adjusted for BMI. For the power calculation, the software G\*Power 3.1.6 was used (Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany).

Results
=======

The SO group presented a significantly lower absolute muscle strength (35.60±7.88 kg \[37.71--38.50 95% CI\] vs 40.30±8.38 kg \[37.32--43.27 95% CI\]) and relative muscle strength (0.51±0.12 kg/kg \[0.47--0.56 95% CI\] vs 0.60±0.12 kg/kg \[0.56--0.65 95% CI\]), arm lean body mass (3.76±0.55 kg \[3.56--3.97 95% CI\] vs 4.02±0.60 kg \[3.80--4.23 95% CI\]), leg lean body mass (10.90±1.28 kg \[10.43--11.37 95% CI\] vs 11.76±1.22 kg \[11.33--12.20 95% CI\]), and aLM (14.67±1.58 kg \[14.09--15.25 95% CI\] vs 15.79±1.60 kg \[15.22--16.36 95% CI\]) compared to the NSO group ([Figure 1](#f1-ijgm-11-443){ref-type="fig"}).

Furthermore, the SO group presented a significantly greater BMI, fat (%), glucose, and a marginal trend toward significance for uric acid, and IL-6 (4.76±5.46 pg/ml \[2.76--6.80 95% CI\] vs 2.58±3.00 pg/ml \[1.51--3.64 95% CI\]) compared to the NSO group ([Table 1](#t1-ijgm-11-443){ref-type="table"}; [Figure 1](#f1-ijgm-11-443){ref-type="fig"}). In addition, there was a significant positive correlation between aLM/BMI with relative muscle strength, arm lean body mass, leg lean body mass, and aLM. However, there was also a significant negative correlation between aLM/BMI with body fat percentage ([Table 2](#t2-ijgm-11-443){ref-type="table"}). Furthermore, a marginal trend was observed for a negative correlation with glucose.

There was no statistical difference between groups for the presence of hypertension (*X*^2^(1) =0.21, *P*=0.80, Cramer's V=0.05) and diabetes (*X*^2^(1) =0.00, *P*=1.00, Cramer's V=0.01).

Discussion
==========

Our results highlight the prevalence of SO in a relatively small sample of obese elderly women using the newly standardized FNIH definition of ALM combined with obesity based on body composition. In addition, our results indicate that elderly women with SO present lower levels of lean body mass and muscle strength, higher glucose, and a trend toward a statistical significance for a higher uric acid and IL-6 serum levels as compared with NSO elderly women. Other important findings include a positive correlation between aLM/BMI with lean body mass and muscle strength, and a negative association with BMI and percentage body fat.

Inflammation associated with SO plays an important role in insulin resistance, glucose tolerance, reduced lean body mass, and lower muscle strength.[@b3-ijgm-11-443],[@b16-ijgm-11-443],[@b26-ijgm-11-443],[@b27-ijgm-11-443] An alternative hypothesis for the higher glucose levels observed in the SO group is that rather than low levels of lean body mass being responsible for glucose intolerance, the condition may instead be primarily a function of the higher accumulation of visceral fat.[@b28-ijgm-11-443]

This might be explained by the superior IL-6 serum levels when compared with the NSO group. In addition, chronic IL-6 elevations activate the transcription nuclear factor-kB and JUN N-terminal kinase pathways associated with insulin resistance,[@b27-ijgm-11-443],[@b29-ijgm-11-443] thus promoting a higher level of glucose in the SO group compared with NSO group as verified in this study.

Furthermore, higher IL-6 serum levels are observed in individuals with obesity and poor muscle strength.[@b16-ijgm-11-443] Consistent with this result, we found a trend for greater IL-6 serum levels in the SO group. Moreover, the low muscle strength and lean body mass observed in the SO group might be explained by the activation of molecular pathways as FOXO, Smad 2/3, p38MAPK promoted by IL-6 that causes protein degradation by the ubiquitin ligases and thereby negatively regulates muscle mass and strength in sarcopenic individuals.[@b30-ijgm-11-443] Although no standard for IL-6 serum levels has been established for reference in clinical practice, older women with high IL-6 serum levels (\>3.10 pg/mL) have a higher risk of developing physical disabilities (eg, associated with low muscle strength) as observed in the present study for the SO group when compared with the NSO group (4.76 vs 2.58 pg/mL for IL-6, respectively).[@b22-ijgm-11-443],[@b26-ijgm-11-443]

On the basis of this finding, SO demonstrated a statistical trend for higher uric acid when compared to NSO group. One possible explanation is that visceral adiposity demonstrates a higher urinary excretion (eg, overproduction-type hyperuricemia).[@b31-ijgm-11-443] In addition, central obesity (aka visceral adiposity) is associated with a proinflammatory condition and insulin resistance.[@b16-ijgm-11-443],[@b32-ijgm-11-443] Central obesity to a greater extent directly affects inflammation, functional impairment, and uric acid serum levels.[@b16-ijgm-11-443],[@b31-ijgm-11-443],[@b33-ijgm-11-443] SO group in our study might have a central obesity characteristic rather than regional obesity when compared with NSO, although not directly verified by DXA. Furthermore, uric acid might also induce insulin resistance, which could partially explain the higher glucose serum levels observed in the SO group.[@b32-ijgm-11-443]

SO has been shown to be related to physical limitations, impaired basic activities of daily living, and impaired instrumental activities of daily living.[@b9-ijgm-11-443] The low muscle strength observed in our SO group may increase the likelihood for these maladies and lead to premature mortality.[@b12-ijgm-11-443] Thus, maintaining a higher aLM/BMI is positively associated with lean body mass and muscle strength while negatively associated with a lower BMI and percent body fat. Furthermore, there was a trend toward a negative association with glucose tolerance, which may have beneficial health implications.

Our exploratory analysis provides additional insight into the relationship between SO, inflammation, low muscle strength, glucose intolerance, and uric acid concentrations. However, these important findings are highly dependent on the specific definitions used for sarcopenia and obesity, which may result in over- or under-diagnosis of this clinical condition.[@b6-ijgm-11-443],[@b11-ijgm-11-443],[@b17-ijgm-11-443]

Accordingly, our findings would necessarily change when a different method is employed.[@b5-ijgm-11-443],[@b7-ijgm-11-443] Although this represents an important limitation, our results corroborate the relationship between SO and functional disabilities and inflammation where using the aLM/BMI method demonstrated stronger strengths of associations and clinical applicability.[@b8-ijgm-11-443],[@b9-ijgm-11-443] Our findings are also limited by the relatively small sample size that compromises statistical power, how well the sample reflected the true underlying population of obese elderly women, and the cross-sectional design employed precludes the determination of causality.

In addition, we suggest the need of other strength measures to be comparable with other studies of sarcopenia and the need for future research including more details regarding visceral fat such as waist--hip ratio or separation of fat deposits using DXA or other imaging measures.

Conclusion
==========

Our results suggest that SO in elderly women is associated with higher IL-6 serum levels, lower muscle strength, lower lean body mass, higher glucose, and higher uric acid levels. Furthermore, the use of definition criteria from FNIH and obesity might permit the identification of elderly women with SO and allow researchers in clinical geriatric practice to plan possible interventions to reduce the burden of disability downstream.[@b6-ijgm-11-443],[@b11-ijgm-11-443],[@b17-ijgm-11-443]
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![Comparisons between sarcopenic obesity and nonsarcopenic obesity presented by mean and SD.\
**Notes:** Non-normal data (relative muscle strength, leg lean mass, appendicular lean mass, and interleukin-6), *P*≤0.05.](ijgm-11-443Fig1){#f1-ijgm-11-443}

###### 

Participant characteristics presented by mean, SD, and 95% CI

                                                                      SO (N=31)                       NSO (N=33)                      *P*-value
  ------------------------------------------------------------------- ------------------------------- ------------------------------- -----------
                                                                                                                                      
  Age (years)[\*](#tfn1-ijgm-11-443){ref-type="table-fn"}             68.19±5.06 (66.33--70.05)       68.51±6.91 (66.06--70.96)       0.859
  Body weight (kg)                                                    70.11±12.82 (65.41--74.82)      66.90±10.42 (63.20--70.59)      0.274
  BMI (kg/m^2^)[\*](#tfn1-ijgm-11-443){ref-type="table-fn"}           31.19±4.35 (29.60--32.79)       27.76±3.98 (26.34--29.17)       0.002
  Height (m)                                                          1.49±0.05 (1.47--1.51)          1.55±0.04 (1.53--1.56)          0.001
  Fat (%)[\*](#tfn1-ijgm-11-443){ref-type="table-fn"}                 45.17±4.46 (43.54--46.81)       42.97±3.54 (41.71--44.22)       0.050
  Fat (kg)[\*](#tfn1-ijgm-11-443){ref-type="table-fn"}                30.44±8.71 (27.24--33.63)       28.47±5.75 (26.43--30.51)       0.532
  aLM/BMI[\*](#tfn1-ijgm-11-443){ref-type="table-fn"}                 0.43±0.03 (0.46--0.48)          0.57±0.08 (0.54--0.60)          0.001
  Total cholesterol (mg/dL)                                           215±32.45 (203.48--227.71)      209.42± (196.72--222.12)        0.482
  Triglycerides (mg/dL)[\*](#tfn1-ijgm-11-443){ref-type="table-fn"}   155.50±57.94 (133.86--177.13)   145.57±62.09 (123.55--167.59)   0.372
  HDL (mg/dL)                                                         47.60±11.69 (43.23--51.96)      46.21±11.35 (42.18--50.24)      0.629
  LDL (mg/dL)                                                         137.24±32.27 (125.18--149.29)   134.06±33.10 (134.06--122.32)   0.711
  Uric acid (mg/dL)                                                   5.10±1.51 (4.53--5.67)          4.48±1.23 (4.05--4.92)          0.084
  Urea (mg/dL)                                                        33.28±7.14 (30.61--35.95)       36.21±8.34 (33.25--39.17)       0.142
  CK (U/L)[\*](#tfn1-ijgm-11-443){ref-type="table-fn"}                94.56±33.82 (81.93--107.19)     104.54±44.00 (88.94--120.14)    0.215
  Glucose (mg/dL)[\*](#tfn1-ijgm-11-443){ref-type="table-fn"}         108.52±39.84 (93.64--123.40)    95.48±21.40 (87.89--103.07)     0.010

**Note:**

Non-normal data.

**Abbreviations:** aLM, appendicular lean mass, BMI, body mass index, HDL, high-density lipoprotein, LDL, low-density lipoprotein, CK, creatine kinase, SO, sarcopenic obesity, NOS, nonsarcopenic obesity.

###### 

Correlation coefficient between aLM/BMI and biochemical parameters, muscle strength, and body composition

                                  Correlation coefficient   
  ------------------------------- ------------------------- -------
                                                            
  IL-6 (pg/mL)                    −0.18                     0.153
  Glucose (mg/dL)                 −0.22                     0.080
  Uric Acid (mg/dL)               −0.15                     0.214
  Absolute muscle strength (kg)   0.17                      0.167
  Relative muscle strength (kg)   0.32                      0.001
  Arms lean body mass (kg)        0.24                      0.056
  Legs lean body mass (kg)        0.32                      0.002
  aLM (kg)                        0.35                      0.004
  BMI (kg/m^2^)                   −0.53                     0.001
  Fat (%)                         −0.39                     0.001

**Note:** *P*≤0.05, significant difference.

**Abbreviations:** IL-6, interleukin-6, aLM, appendicular lean mass, BMI, body mass index.
